CASRN: 171500-79-1
Drug Levels and Effects
Summary of Use during Lactation
Dalbavancin is 93% plasma protein bound and is poorly absorbed orally, so it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. If dalbavancin is required by the mother, it is not a reason to discontinue breastfeeding. Monitor the infant for possible effects on the gastrointestinal tract, such as diarrhea, vomiting, and candidiasis (e.g., thrush, diaper rash).
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, Vancomycin
Substance Identification
Substance Name
Dalbavancin
CAS Registry Number
171500-79-1
Drug Class
Breast Feeding
Lactation
Anti-Infective Agents
Anti-Bacterial Agents
Glycopeptides
Lipoglycopeptides
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: September 21, 2020.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Dalbavancin. [Updated 2020 Sep 21].